Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NHWK | Stock Option (right to buy) | Other | $0 | -130K | -100% | $0.00* | 0 | Dec 30, 2021 | Common Stock | 130K | $4.06 | Direct | F1 |
transaction | NHWK | Stock Option (right to buy) | Award | $0 | +130K | $0.00 | 130K | Dec 30, 2021 | Common Stock | 130K | $4.06 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | On December 30, 2021, the board of directors of Heat Biologics, Inc. (the "Company") rescinded and cancelled stock option awards previously made to Dr. Prendergast on December 13, 2021 covering 129,820 shares under the Company's 2018 Stock Incentive Plan (the "Plan") and granted new stock options under the Plan, on substantially similar terms to the rescinded stock options, which new stock options are subject to forfeiture in the event an amendment to increase the number of shares of common stock available for grant under the Plan is not adopted by the Company's stockholders. |
F2 | These stock options vest pro rata on a monthly basis over a twelve- month period commencing 1/13/2022 |